0.00Open0.03Pre Close0 Volume0 Open Interest6.00Strike Price0.00Turnover1802.55%IV17.31%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier-5DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type-0.0633Delta0.1204Gamma240.67Leverage Ratio-2.8150Theta0.0000Rho-15.24Eff Leverage0.0001Vega
Mind Medicine Stock Discussion
Benzinga· 2 mins ago
Rob Barrow, Chief Executive Officer of MindMed, said, "This marks a significant milestone for MindMed and for the millions of individuals affected by GAD. We are on schedule to initiate our Phase 3 clinical program for MM120 oral dissolving tablet (ODT) in GAD in the second half of this ...
A panel of advisors to the U.S. FDA declined to endorse Lykos Therapeutics' application to market to psychedelic drug MDMA, also known as ecstasy, as a treatment for post-traumatic stress disorder.
The Psychopharmacologic Drugs Advisory Committee held votes on twoquestions. The first dealt was the drug's efficacy in PTSD, while the second aske...
Benzinga· just
GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life-
-People with Undiagnosed GAD Incur Even Higher Total Healthcare Costs than those Diagnosed with GAD-
-Comprehensive Analyses of GAD Disease Burden in the US Conducted by MindMed; Company is Investigating New Treatments...
NEWS
MindMed Reports First Quarter 2024 Financial Results and Business Updates
MindMed received Breakthrough Therapy Designation (BTD) from the FDA for MM120 in the treatment of GAD in adults, after positive Phase 2b results showing statistically significant activity through 12 weeks.
The Company has a strong financial position with $252.3 million in cash and cash equivalents as of March 31, 2024, sufficient to fund operations into 2026.
MindMed is on track to begin its ...
No comment yet